Adiponectinemia, inflammatory process activity, and endothelial dysfunction in patients with type 2 diabetes and acute coronary syndrome with ST elevation in relation to the severity of lesions in the coronary arteries;Adiponektynemia oraz aktywność procesu zapalnego i dysfunkcja śródblonka u chorych na cukrzycȩ typu 2 i na ostry zespół wieńcowy z uniesieniem ST w zależności od stopnia zaawansowania zmian w tetnicach wieńcowych

Polskie Archiwum Medycyny Wewnetrznej

Volumn 117, Issue 8, 2007, Pages 343-349

  Miłosz, Danuta ^a,b   Czupryniak, Leszek ^a   Saryusz Wolska, Małgorzata ^a   Zasadzińska, Grazyna ^a   Borkowska, Anna ^a   Cieplucha, Elzbieta ^a   Chizyński, Krzysztof ^a   Loba, Jerzy ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b N Barlicki University Hospital No 1 of Medical University of Lodz   (Poland)

Author keywords

Acute coronary syndrome; Adiponectin; Endothelial dysfunction; Inflammation; Type 2 diabetes

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CREATINE KINASE MB; CYTOKINE; FIBRINOGEN; GLUCOSE; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; ISOENZYME; LIPID; SULFONYLUREA DERIVATIVE; TROPONIN T;

ACUTE CORONARY SYNDROME; ADIPONECTINEMIA; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; FEMALE; GENSINI SCORE; HEART INFARCTION; HUMAN; INFLAMMATION; LEUKOCYTOSIS; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; SCORING SYSTEM; ST SEGMENT ELEVATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 35748946022     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.178     Document Type: Article

References (33)

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. Epidemiology, pathophysiology and management. JAMA. 2002; 287:2570-2581.
2. Marso SP. Optimizing the diabetic formulary: beyond aspirin and isulin. J Am Coll Cardiol. 2002; 40: 652-661.
3. Plutzky J, Viberti G, Haffner S. Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic target. J Diabetes and Its Complication. 2002; 16: 401-415.
4. Tatoń J, Czech A. Etiologia i patogeneza angiopatii cukrzycowej. In: Tatoń J, Czech A, eds. Diabetologia. Tom 2. Warszawa, PZWL, 2001; 27: 2-22.
5. Morgan KP, Kapur A, Beatt KJ. Anatomy of coronary disease in diabetic patients: an explanation for poorer outcomes after percutaneous coronary intervention and potential target for intervention. Heart. 2004; 90: 732-738.
6. Nesto RW. Correlation between cardiovascular disease and diabetes mellitus: current concepts. Am J Med. 2004, 116(5A): S11-S22.
7. Reaven GM, Lithell RR, Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and sympathoadrenal system. N Engl J Med. 1996; 334: 374-381.
8. Goraya TY, Leibson CL, Palumbo PJ. Coronary atherosclerosis in diabetes mellius: a population-based autopsy study. J Am Coll Cardiol. 2002; 40: 946-953.
9. Ross R. Atherosclerosis is an inflammatory diseases. Am Heart J. 1999; 138: S419-S420.
10. Libby P. Inflammation in atherosclerosis. Nature. 2002; 8: 1227-1234.
11. 1q, produced exclusively in adipocytes. J Biol Chem. 1995; 270:26747-26749.
12. Chandran M, Phillips S. Adiponectin: more than just another fat cell hormon? Diabetes Care. 2003; 26: 2442-2450.
13. Maeda K, Okubo K, Shimomura I, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apMI. Biochem Biophys Res Commun. 1996; 221: 286-289.
14. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999; 257: 79-83.
15. Yokota T, Oritani K, Takahashi I. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of the macrophages. Blood. 2000; 96: 1723-1732.
16. Ouchi N, Kihara S, Arita Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF kβ signaling throught a cAMP-dependent pathway. Circulation. 2000; 102: 1296-1301.
17. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules. Adipocyte derived plasma protein adiponectin. Circutation. 1999; 100: 2473-2476.
18. Stanisz A. Przystepny kurs statystyki. Kraków, StatSoft Polska, 2007.
19. Barrett-Connor E, Conn BA, Wingard DL, et al. Why is diabetes mellitus a stronger factor for fatal ischaemic heart disease in women than in men? The Rancho Bernardo Study. JAMA. 1991; 265: 627-631.
20. Garcia MJ, Mc Namara PM, Gordon T, et al. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up. Diabetes. 1974, 23: 105-111.
21. Scaaeffler A, Herfarth H, Paul G, et al. Identification of influencing variables on adiponectin, serum levels in diabetes mellitus type 1 and type 2. Exp Clin Endocrinol Diabetes. 2004; 112: 383-389.
22. Miyazaki T, Shimada K, Mokuno H. Adipocyte derived protein, adiponectin, is associated with smoking status in patients with coronary artery diseases. Heart. 2003; 89: 663-664.
23. Looker HC, Krakoff J, Funahashi T, et al. Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J Clin Endocrinol Metab. 2004; 89: 4010-4017.
24. Versaci F, Tomai F, Gaspardone A. Assessment of C-reactive protein levels after percutaneous transluminal coronary angioplasty and stent implantation. Eur Heart J. 1996, 17: 256.
25. Morrow D, Rifai N, Antman E, et al. C-reactiye protein is a potent predictor of mortality independently and in combination with troponin T in acute coronary syndromes. J Am Coll Cardiol. 1998; 31: 1460-1465.
26. Pudil R, Pidrman V, Krejsch J, et al. Cytokines and adhesion molecules in myocardial infarction. Clin Chim Acta. 1999; 280: 127-134.
27. Moukarbel GV, Amaout MSA, Alam SE. C-reactive protein is a marker for a complex culprit lesion anatomy in unstable angina. Eur Heart J. 2000; 21: 83.
28. Meade T, North B, Chakrabarti R, et al. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet. 1980; 1: 1050-1054.
29. Woodward M, Lowe G, Rumley A, et al. Fibrinogen as a risk factor for coronary heart diseases and mortality in middle-aged men and women. Eur Heart J. 1998; 19: 52-56.
30. Abrignani MG, Novo G, Di Girolamo A, et al. Increasesd plasma levels of fibrinogen in acute and chronic ischaemic coronary syndromes. Cardiologia. 1999; 44: 1047-1052.
31. Filipiak K, Opolski G. Parametry odczynu zapalnego w ostrych zespolach wieńcowych. In: Opolski G, Filipiak K, Polonski L. eds. Ostre zespoly wieńcowe. Wrocław, Urban & Partner, 2002; 62-66.
32. Wallen NH, Held C, Rehnqvist N, et al. Elevated sICAM-1 and sVCAM-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction. Eur Heart J. 1999; 14: 1039-1043.
33. Mulvihill N, Foley JB, Murthy RT, et al. Evidence of sustained inflammation in patients with acute coronary syndromes. J Am Coll Cardiol. 2000; 36: 1210-1216.